Mevalotin

pravastatin /prav·a·stat·in/ (prav´ah-stat″in) an antihyperlipidemic agent that acts by inhibiting cholesterol synthesis, used as the sodium salt in the treatment of hypercholesterolemia and other forms of dyslipidemia and to lower the risks associated with atherosclerosis and coronary heart disease.

prav·a·stat·in (pr

-st

A statin drug used to treat hyperlipidemia.

pravastatin

[prav′ahstat′in]

an antihyperlipidemic agent that acts by inhibiting cholesterol synthesis, used as the sodium salt in the treatment of hypercholesterolemia and other forms of dyslipidemia and to lower the risks associated with atherosclerosis and coronary heart disease. It is administered orally.

pravastatin [prav´ah-stat″in]

pravastatin (prav´

stat´

n),

n brand name: Pravachol;
drug class: antihyperlipidemic;
action: inhibits HMG-CoA reductase enzyme, which reduces cholesterol synthesis;
use: as an adjunct in primary hypercholesterolemia (types IIa, IIb).

Mentioned in	?		References in periodicals archive	?		Medical browser	?		Full browser	?
-statin ADMIT ALLHAT C-reactive protein care Cholesterol, High Cholesterol-Reducing Drugs darunavir ethanolate high cholesterol hypercholesterolemia hyperlipoproteinemia lipid MERCURY I orlistat PLAC I/II PRAVA-II Pravachol pravastatin sodium Prezista	Although sales of Olmetec grew substantially in Europe and the United States, they failed to offset a fall in sales of mainstay lipid-lowering drug Mevalotin and effects of the withdrawal from some of its medical goods operations, Sankyo said. LEAD: Sankyo reports 11% surge in FY 2004 group net profit by Japan Weekly Monitor Sankyo said a sharp rise in bulk exports of its mainstay Mevalotin drug for hyperlipidemia to the United States helped offset a sales decline in the domestic market caused by increased competition and the launch of a generic drug. Sankyo's FY 2003 net profit up 28.3% on strong overseas sales by Japan Weekly Monitor Sankyo said bulk shipments of its blockbuster drug, Mevalotin hyperlipidemia agent, surged during the six months to help offset a sales slowdown in the domestic market where the drug's patent had expired and generic competition is heating up. Sankyo's 1st-half group net profit rises 5.3% by Japan Weekly Monitor	metrophlebitis metroplasty Metropolitan Life table metroptosis metrorrhagia metrorrhea metrorrhexis metrosalpingitis metrosalpingography metroscope Metrosexual metrostaxis metrostenosis Metsovo Lung metyrapone metyrosine Metzenbaum scissors Meuse Fever Meuse-Rhine-Yssel MeV Mevacor Meval mevalonate kinase mevalonic acid mevalonic aciduria Mevalotin mevinphos mew Mexican Mexican bindweed Mexican Divorce Mexican Green Mexican Hat Cell Mexican Horse Mexican Locoweed Mexican Mud Mexican Mushroom Mexican Red Mexican Reds Mexican scammony Mexican spotted fever Mexican typhus Mexican Valium Mexico City Policy mexiletine mexiletine HCl mexiletine hydrochloride Mexitil Meyenburg complexes Meyer Meyerding retractors	Meuse-Argonne operation Meuse-Rhine Operation of 1945 Meuse-Rhine-Yssel Meusli Meusnier's theorem Meusnier, Jean Baptiste Marie MEUSOC MEUSP Meute MEUW MeV MeV MeV MeV MeV Ci MEVA Mevac Mevacor Mevacor MEVAG Meval Mevalonate Mevalonate Mevalonate kinase Mevalonate kinase Mevalonate Uptake Facilitator Mevalonic acid Mevalonic acid Mevalonic aciduria Mevalonicaciduria Mevalotin MEVATEC MEVC MEVDP MEVE MEVE MEVI mevinphos Mevis Neurosurgery Planning System Mevlevi Mevlud MEVM MEVO MEVOC mevrou Mevrouw MEVS MEVS+ MEVVA MEVW MEVZA mew mew mew mew mew mew gull mew gulls Mew Mew Power Mew Mew Power Uncensored

Mentioned in

References in periodicals archive

Medical browser

Full browser

-statin
ADMIT
ALLHAT
C-reactive protein
care
Cholesterol, High
Cholesterol-Reducing Drugs
darunavir ethanolate
high cholesterol
hypercholesterolemia
hyperlipoproteinemia
lipid
MERCURY I
orlistat
PLAC I/II
PRAVA-II
Pravachol
pravastatin sodium
Prezista

Although sales of Olmetec grew substantially in Europe and the United States, they failed to offset a fall in sales of mainstay lipid-lowering drug Mevalotin and effects of the withdrawal from some of its medical goods operations, Sankyo said.

LEAD: Sankyo reports 11% surge in FY 2004 group net profit by Japan Weekly Monitor

Sankyo said a sharp rise in bulk exports of its mainstay Mevalotin drug for hyperlipidemia to the United States helped offset a sales decline in the domestic market caused by increased competition and the launch of a generic drug.

Sankyo's FY 2003 net profit up 28.3% on strong overseas sales by Japan Weekly Monitor

Sankyo said bulk shipments of its blockbuster drug, Mevalotin hyperlipidemia agent, surged during the six months to help offset a sales slowdown in the domestic market where the drug's patent had expired and generic competition is heating up.

Sankyo's 1st-half group net profit rises 5.3% by Japan Weekly Monitor

pravastatin (redirected from Mevalotin)

pravastatin
(redirected from Mevalotin)